Compass Therapeutics appoints Chiniara and Gray to board; Toledano departs

Compass Therapeutics, Inc.

Ellen Chiniara (former Alexion Chief Legal Officer) and Mary Ann Gray (Gray Strategic Advisors) join as Class I directors.
Both deemed independent; Chiniara also appointed to Nominating/Governance and Compensation committees.
Each non-employee director receives $45K cash retainer and initial option on 45,000 shares vesting over four years.
Miranda Toledano will not stand for reelection at May 24, 2022 annual meeting; no disagreement cited.
Appointments aim to support pipeline advancement and shareholder value creation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Miranda Toledano

Director

CMPX · Compass Therapeutics, Inc.

Effective: 2022-05-24
Filed: April 26, 2022, 7:59 PM ET

On April 22, 2022, Miranda Toledano, M.B.A., a member of the Board of the Company, notified the Company that she is declining to stand for reelection to the Board at the completion of her current term, ending at the Company’s Annual Meeting of Stockholders set for May 24, 2022.

Appointed

Ellen Chiniara

Director

CMPX · Compass Therapeutics, Inc.

Effective: 2022-04-25
Filed: April 26, 2022, 7:59 PM ET

On April 25, 2022, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed two new directors to its Board: Ellen Chiniara, J.D., former Chief Legal Officer of Alexion Pharmaceuticals; and Mary Ann Gray, Ph.D., President of Gray Strategic Advisors.

Appointed

Mary Ann Gray

Director

CMPX · Compass Therapeutics, Inc.

Effective: 2022-04-25
Filed: April 26, 2022, 7:59 PM ET

On April 25, 2022, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed two new directors to its Board: Ellen Chiniara, J.D., former Chief Legal Officer of Alexion Pharmaceuticals; and Mary Ann Gray, Ph.D., President of Gray Strategic Advisors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Miranda Toledano departed as Director at Compass Therapeutics, Inc..

Action: declined to stand for reelection
Role: Director

Exact text from the filing

On April 22, 2022, Miranda Toledano, M.B.A., a member of the Board of the Company, notified the Company that she is declining to stand for reelection to the Board at the completion of her current term, ending at the Company’s Annual Meeting of Stockholders set for May 24, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ellen Chiniara was appointed as Director at Compass Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 25, 2022, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed two new directors to its Board: Ellen Chiniara, J.D., former Chief Legal Officer of Alexion Pharmaceuticals; and Mary Ann Gray, Ph.D., President of Gray Strategic Advisors.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mary Ann Gray was appointed as Director at Compass Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 25, 2022, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed two new directors to its Board: Ellen Chiniara, J.D., former Chief Legal Officer of Alexion Pharmaceuticals; and Mary Ann Gray, Ph.D., President of Gray Strategic Advisors.

View on SEC.gov

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-002790

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.